Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says

Executive Summary

Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.

You may also be interested in...



FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

House Energy and Commerce Committee refines FDA Reauthorization Act and adopts a ‘sense of Congress’ resolution on drug pricing, but largely steers clear of other potentially controversial add-ons that could bog down the measure.

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions

Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.

Related Content

Topics

UsernamePublicRestriction

Register

GB002066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel